PARAGON Care Limited has successfully finalised its merger with CH2 Holdings Pty Limited, marking a significant transformation for the company into a prominent healthcare wholesaler, distributor, and manufacturer across the Asia Pacific region.
The merger, completed on 03 Jun, saw David Collins assume the role of CEO, while Peter Lacaze was appointed Chairman.
Under the merger terms, Paragon acquired all issued share capital of CH2, dispersing over 943 million ordinary shares to shareholders, including the Lacaze and Collins Millar Family Trusts.
The restructuring extended to the board of directors, with Shane Tanner, Geoffrey Sam, and Brent Stewart resigning, and David Collins, Carmen Riley, and Peter Lacaze joining.
John Walstab stepped down as Managing Director, succeeded by David Collins, who brings over two decades of healthcare industry expertise from his tenure as CH2's Managing Director.
Michael Peters will retain his position as Chief Financial Officer of the merged entity, to ensure continuity in financial management amid the strategic evolution. JG
The above article was sent to subscribers in Pharmacy Daily's issue from 07 Jun 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Jun 24
